Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Erythropoietin plus ozone versus sodium hyaluronate + chondroitin sulfate plus ozone for knee osteoarthritis
IRCT20190503043450N1Phase 3Completed
- Sponsor
- Zahedan University of Medical Sciences
- Start
- May 2019
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of erythropoietin, medical ozonated water, sodium hyaluronate and chondroitin sulfate in knee osteoarthritis (OA) (2 arms), sponsored by Zahedan University of Medical Sciences. Primary endpoint: Knee pain. Started May 2019; status: completed.
02
Drugs
erythropoietinmedical ozonated watersodium hyaluronatechondroitin sulfate
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on IRCT20190503043450N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190503043450N1.